Last reviewed 2026-05-27 · How we verify

ZP Vehicle

Zurex Pharma, Inc. · Phase 3 active Small molecule ✓ Verified May 2026

ZP Vehicle is a Small molecule drug developed by Zurex Pharma, Inc.. It is currently in Phase 3 development. Also known as: ZP without IPA.

ZP Vehicle is a formulation vehicle used to deliver active pharmaceutical ingredients.

ZuraPrep Vehicle is a topical solution used in surgical skin preparation. It is being clinically evaluated for its antimicrobial effectiveness in a study titled "Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZuraPrep".

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ZP Vehicle
Also known as	ZP without IPA
Sponsor	Zurex Pharma, Inc.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

It is designed to provide a stable and consistent release of the active ingredient, improving bioavailability and efficacy. The exact mechanism of action depends on the specific active ingredient being delivered.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

In-vivo Efficacy of Patient Preoperative Prep, ZuraPrep (ZP) (PHASE3)
In-vivo Efficacy of Patient Preoperative Prep (PHASE3)
Clinical Evaluation of Patient Preoperative Prep (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ZP Vehicle CI brief — competitive landscape report
ZP Vehicle updates RSS · CI watch RSS
Zurex Pharma, Inc. portfolio CI

Frequently asked questions about ZP Vehicle

What is ZP Vehicle?

ZP Vehicle is a Small molecule drug developed by Zurex Pharma, Inc..

How does ZP Vehicle work?

ZP Vehicle is a formulation vehicle used to deliver active pharmaceutical ingredients.

Who makes ZP Vehicle?

ZP Vehicle is developed by Zurex Pharma, Inc. (see full Zurex Pharma, Inc. pipeline at /company/zurex-pharma-inc).

Is ZP Vehicle also known as anything else?

ZP Vehicle is also known as ZP without IPA.

What development phase is ZP Vehicle in?

ZP Vehicle is in Phase 3.

Manufacturer: Zurex Pharma, Inc. — full pipeline
Also known as: ZP without IPA

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing